Research programme: Crohn's disease therapeutics - Enterome/Janssen Biotech

Drug Profile

Research programme: Crohn's disease therapeutics - Enterome/Janssen Biotech

Alternative Names: EB 110

Latest Information Update: 19 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enterome
  • Class Bacterial proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Crohn's disease

Most Recent Events

  • 07 Jan 2016 Enterome and Janssen Biotech enter into collaboration to develop Crohn's disease therapeutics for the treatment of Crohn's disease
  • 01 Jul 2015 Preclinical trials in Crohn's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top